Review



aβ42 expression plasmid  (Polysciences inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Polysciences inc aβ42 expression plasmid
    Antibodies that were conjugated to magnetic beads to capture antigens.
    Aβ42 Expression Plasmid, supplied by Polysciences inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aβ42 expression plasmid/product/Polysciences inc
    Average 90 stars, based on 1 article reviews
    aβ42 expression plasmid - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue"

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    Journal: Laboratory investigation; a journal of technical methods and pathology

    doi: 10.1038/s41374-018-0165-x

    Antibodies that were conjugated to magnetic beads to capture antigens.
    Figure Legend Snippet: Antibodies that were conjugated to magnetic beads to capture antigens.

    Techniques Used: Magnetic Beads

    Antibodies that were biotinylated to detect captured antigens.
    Figure Legend Snippet: Antibodies that were biotinylated to detect captured antigens.

    Techniques Used:

    Validation of recombinant Aβ42 standards. (a) Quantification of recombinant Aβ42 using commercial Innogenetics-kit standards and the Innogenetics kit. (b) Comparison of serial dilutions of Innogenetics-kit and recombinant Aβ42 standards measured with the Innogenetics kit. (c) Generation of a standard curve with recombinant Aβ42 standards measured with our newly developed Luminex assay. (d) Test-retest of serially diluted recombinant Aβ42 standards measured with our newly developed Luminex assay. All data are presented as mean ± SEM.
    Figure Legend Snippet: Validation of recombinant Aβ42 standards. (a) Quantification of recombinant Aβ42 using commercial Innogenetics-kit standards and the Innogenetics kit. (b) Comparison of serial dilutions of Innogenetics-kit and recombinant Aβ42 standards measured with the Innogenetics kit. (c) Generation of a standard curve with recombinant Aβ42 standards measured with our newly developed Luminex assay. (d) Test-retest of serially diluted recombinant Aβ42 standards measured with our newly developed Luminex assay. All data are presented as mean ± SEM.

    Techniques Used: Recombinant, Luminex

    Determination of optimal FFPE sample amounts for Luminex analysis of Aβ42, and quantification of Aβ42 in FFPE tissue from cases with Not/Low, Intermediate and High NIA-AA AD severity. (a) Fluorescent-intensity signals for Aβ42 as function of increasing amounts of guanidine-soluble extracts from middle frontal gyrus. (b) Aβ42 levels in MFG samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (c) Aβ42 levels in hippocampal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (d) Aβ42 levels in neostriatal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). Aβ42 levels in panels (b-d) are normalized to the amount of guanidine-soluble protein (pg per μg). All data are presented as mean ± SEM. ★ p < 0.05 and ★★ p < 0.01.
    Figure Legend Snippet: Determination of optimal FFPE sample amounts for Luminex analysis of Aβ42, and quantification of Aβ42 in FFPE tissue from cases with Not/Low, Intermediate and High NIA-AA AD severity. (a) Fluorescent-intensity signals for Aβ42 as function of increasing amounts of guanidine-soluble extracts from middle frontal gyrus. (b) Aβ42 levels in MFG samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (c) Aβ42 levels in hippocampal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (d) Aβ42 levels in neostriatal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). Aβ42 levels in panels (b-d) are normalized to the amount of guanidine-soluble protein (pg per μg). All data are presented as mean ± SEM. ★ p < 0.05 and ★★ p < 0.01.

    Techniques Used: Luminex

    Scatter plots of Luminex fluorescent signal intensities for Aβ42 and pTau in MFG, hippocampus and neostriatum. We performed correlation analyses of Aβ42 and pTau signals across all analyzed brain regions and confirmed the following statistically significant positive correlations. (a) Aβ42 levels in MFG vs. Aβ42 levels in hippocampus. (b) Aβ42 levels in MFG vs. Aβ42 levels in neostriatum. (c) Aβ42 levels in hippocampus vs. Aβ42 levels in neostriatum. (d) Aβ42 levels in neostriatum vs. pTau levels in MFG. (e) pTau levels in MFG vs. pTau levels in hippocampus. Statistically significant R 2 values are shown in each scatter plot.
    Figure Legend Snippet: Scatter plots of Luminex fluorescent signal intensities for Aβ42 and pTau in MFG, hippocampus and neostriatum. We performed correlation analyses of Aβ42 and pTau signals across all analyzed brain regions and confirmed the following statistically significant positive correlations. (a) Aβ42 levels in MFG vs. Aβ42 levels in hippocampus. (b) Aβ42 levels in MFG vs. Aβ42 levels in neostriatum. (c) Aβ42 levels in hippocampus vs. Aβ42 levels in neostriatum. (d) Aβ42 levels in neostriatum vs. pTau levels in MFG. (e) pTau levels in MFG vs. pTau levels in hippocampus. Statistically significant R 2 values are shown in each scatter plot.

    Techniques Used: Luminex

    Correlations (R 2 ) between Aβ42 and pTau levels in MFG, hippocampus and neostriatum in all analyzed samples. Statistically significant correlation coefficients are marked: ★ p < 0.05 and ★★ p < 0.01.
    Figure Legend Snippet: Correlations (R 2 ) between Aβ42 and pTau levels in MFG, hippocampus and neostriatum in all analyzed samples. Statistically significant correlation coefficients are marked: ★ p < 0.05 and ★★ p < 0.01.

    Techniques Used:

    Association of Aβ42 and pTau levels with genetic risk for AD. (a) Aβ42 and (b) pTau levels in MFG, hippocampus and neostriatum of samples from cases with no APOE-ε4 allele (n = 18) and with at least one APOE-ε4 allele (n = 11). All data are presented as mean ± SEM.
    Figure Legend Snippet: Association of Aβ42 and pTau levels with genetic risk for AD. (a) Aβ42 and (b) pTau levels in MFG, hippocampus and neostriatum of samples from cases with no APOE-ε4 allele (n = 18) and with at least one APOE-ε4 allele (n = 11). All data are presented as mean ± SEM.

    Techniques Used:



    Similar Products

    aβ42-gfp yeast expression plasmid  (Addgene inc)
    90
    Addgene inc aβ42-gfp yeast expression plasmid
    Aβ42 Gfp Yeast Expression Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aβ42-gfp yeast expression plasmid/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    aβ42-gfp yeast expression plasmid - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    aβ42 expression plasmid  (Polysciences inc)
    90
    Polysciences inc aβ42 expression plasmid
    Antibodies that were conjugated to magnetic beads to capture antigens.
    Aβ42 Expression Plasmid, supplied by Polysciences inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aβ42 expression plasmid/product/Polysciences inc
    Average 90 stars, based on 1 article reviews
    aβ42 expression plasmid - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Antibodies that were conjugated to magnetic beads to capture antigens.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Antibodies that were conjugated to magnetic beads to capture antigens.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques: Magnetic Beads

    Antibodies that were biotinylated to detect captured antigens.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Antibodies that were biotinylated to detect captured antigens.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques:

    Validation of recombinant Aβ42 standards. (a) Quantification of recombinant Aβ42 using commercial Innogenetics-kit standards and the Innogenetics kit. (b) Comparison of serial dilutions of Innogenetics-kit and recombinant Aβ42 standards measured with the Innogenetics kit. (c) Generation of a standard curve with recombinant Aβ42 standards measured with our newly developed Luminex assay. (d) Test-retest of serially diluted recombinant Aβ42 standards measured with our newly developed Luminex assay. All data are presented as mean ± SEM.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Validation of recombinant Aβ42 standards. (a) Quantification of recombinant Aβ42 using commercial Innogenetics-kit standards and the Innogenetics kit. (b) Comparison of serial dilutions of Innogenetics-kit and recombinant Aβ42 standards measured with the Innogenetics kit. (c) Generation of a standard curve with recombinant Aβ42 standards measured with our newly developed Luminex assay. (d) Test-retest of serially diluted recombinant Aβ42 standards measured with our newly developed Luminex assay. All data are presented as mean ± SEM.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques: Recombinant, Luminex

    Determination of optimal FFPE sample amounts for Luminex analysis of Aβ42, and quantification of Aβ42 in FFPE tissue from cases with Not/Low, Intermediate and High NIA-AA AD severity. (a) Fluorescent-intensity signals for Aβ42 as function of increasing amounts of guanidine-soluble extracts from middle frontal gyrus. (b) Aβ42 levels in MFG samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (c) Aβ42 levels in hippocampal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (d) Aβ42 levels in neostriatal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). Aβ42 levels in panels (b-d) are normalized to the amount of guanidine-soluble protein (pg per μg). All data are presented as mean ± SEM. ★ p < 0.05 and ★★ p < 0.01.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Determination of optimal FFPE sample amounts for Luminex analysis of Aβ42, and quantification of Aβ42 in FFPE tissue from cases with Not/Low, Intermediate and High NIA-AA AD severity. (a) Fluorescent-intensity signals for Aβ42 as function of increasing amounts of guanidine-soluble extracts from middle frontal gyrus. (b) Aβ42 levels in MFG samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (c) Aβ42 levels in hippocampal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). (d) Aβ42 levels in neostriatal samples from cases with varying NIA-AA AD severity (Not/Low: n = 10, Intermediate: n = 10, High: n = 9). Aβ42 levels in panels (b-d) are normalized to the amount of guanidine-soluble protein (pg per μg). All data are presented as mean ± SEM. ★ p < 0.05 and ★★ p < 0.01.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques: Luminex

    Scatter plots of Luminex fluorescent signal intensities for Aβ42 and pTau in MFG, hippocampus and neostriatum. We performed correlation analyses of Aβ42 and pTau signals across all analyzed brain regions and confirmed the following statistically significant positive correlations. (a) Aβ42 levels in MFG vs. Aβ42 levels in hippocampus. (b) Aβ42 levels in MFG vs. Aβ42 levels in neostriatum. (c) Aβ42 levels in hippocampus vs. Aβ42 levels in neostriatum. (d) Aβ42 levels in neostriatum vs. pTau levels in MFG. (e) pTau levels in MFG vs. pTau levels in hippocampus. Statistically significant R 2 values are shown in each scatter plot.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Scatter plots of Luminex fluorescent signal intensities for Aβ42 and pTau in MFG, hippocampus and neostriatum. We performed correlation analyses of Aβ42 and pTau signals across all analyzed brain regions and confirmed the following statistically significant positive correlations. (a) Aβ42 levels in MFG vs. Aβ42 levels in hippocampus. (b) Aβ42 levels in MFG vs. Aβ42 levels in neostriatum. (c) Aβ42 levels in hippocampus vs. Aβ42 levels in neostriatum. (d) Aβ42 levels in neostriatum vs. pTau levels in MFG. (e) pTau levels in MFG vs. pTau levels in hippocampus. Statistically significant R 2 values are shown in each scatter plot.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques: Luminex

    Correlations (R 2 ) between Aβ42 and pTau levels in MFG, hippocampus and neostriatum in all analyzed samples. Statistically significant correlation coefficients are marked: ★ p < 0.05 and ★★ p < 0.01.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Correlations (R 2 ) between Aβ42 and pTau levels in MFG, hippocampus and neostriatum in all analyzed samples. Statistically significant correlation coefficients are marked: ★ p < 0.05 and ★★ p < 0.01.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques:

    Association of Aβ42 and pTau levels with genetic risk for AD. (a) Aβ42 and (b) pTau levels in MFG, hippocampus and neostriatum of samples from cases with no APOE-ε4 allele (n = 18) and with at least one APOE-ε4 allele (n = 11). All data are presented as mean ± SEM.

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Luminex-based quantification of Alzheimer’s Disease neuropathologic change in formalin-fixed post-mortem human brain tissue

    doi: 10.1038/s41374-018-0165-x

    Figure Lengend Snippet: Association of Aβ42 and pTau levels with genetic risk for AD. (a) Aβ42 and (b) pTau levels in MFG, hippocampus and neostriatum of samples from cases with no APOE-ε4 allele (n = 18) and with at least one APOE-ε4 allele (n = 11). All data are presented as mean ± SEM.

    Article Snippet: We then transfected HEK cells with the Aβ42 expression plasmid using polyethylenimine (PEI, Polysciences; Warrington, PA) transfection.

    Techniques: